Mitchell J. Spirt
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Mitchell J. Spirt has a total of 1 co-authors. Here are the top co-authors by number of shared publications:
Md
Division of Gastroenterology, School of Medicine, University of California Los Angeles, Los Angeles, CA
1 shared publication
Latest Publications
- 1 January 2010
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 122 (1) , 39-51
Complicated Intra-abdominal Infections: A Focus on Appendicitis and Diverticulitis
Severe abdominal pain is a common complaint encountered by primary care and emergency room physicians. Caused by many conditions, including appendicitis and diverticulitis, severe abdominal pain may be a diagnostic challenge. Although different in many ways, appendicitis and diverticulitis are caused by obstruction of a blind pouch that leads to inflammation of the structure and surrounding tissue. Appendicitis and diverticulitis are 2 of the most frequently diagnosed causes of complicated intra-abdominal infections. Combined, appendicitis and diverticulitis comprise > 80% of all community-acquired complicated intra-abdominal infections. These conditions are serious and require prompt diagnosis and treatment. Because complicated intra-abdominal infections are typically polymicrobial, a wide variety of causative pathogens are identified, including Gram-positive and Gram-negative aerobic and anaerobic microorganisms. Treatment for these disorders often requires surgical and medical management. Altho...
- 1 January 2010
- Published by Taylor & Francis in Postgraduate Medicine
- Vol. 122 (1) , 39-51
Complicated Intra-abdominal Infections: A Focus on Appendicitis and Diverticulitis
Severe abdominal pain is a common complaint encountered by primary care and emergency room physicians. Caused by many conditions, including appendicitis and diverticulitis, severe abdominal pain may be a diagnostic challenge. Although different in many ways, appendicitis and diverticulitis are caused by obstruction of a blind pouch that leads to inflammation of the structure and surrounding tissue. Appendicitis and diverticulitis are 2 of the most frequently diagnosed causes of complicated intra-abdominal infections. Combined, appendicitis and diverticulitis comprise > 80% of all community-acquired complicated intra-abdominal infections. These conditions are serious and require prompt diagnosis and treatment. Because complicated intra-abdominal infections are typically polymicrobial, a wide variety of causative pathogens are identified, including Gram-positive and Gram-negative aerobic and anaerobic microorganisms. Treatment for these disorders often requires surgical and medical management. Altho...
- 1 February 2004
- Published by Elsevier in Clinical Therapeutics
- Vol. 26 (2) , 197-213
Stress-related mucosal disease: Risk factors and prophylactic therapy
- 1 February 2004
- Published by Elsevier in Clinical Therapeutics
- Vol. 26 (2) , 197-213
Stress-related mucosal disease: Risk factors and prophylactic therapy
- 1 October 2003
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 23 (10P2) , 87S-93S
Acid Suppression in Critically Ill Patients: What Does the Evidence Support?
Stress‐related mucosal disease is a frequent complication in critically ill patients. A wealth of evidence suggests that hypoperfusion to the upper gastrointestinal tract can lead to ulceration and is associated with increased morbidity. Management of stress ulcers depends on aggressive therapy that includes acid‐suppressive agents. Proton pump inhibitors (PPIs) have gained recognition as a potentially important therapy for treatment and prevention of upper gastrointestinal bleeding in critically ill patients. Patients who present to the hospital with acute gastrointestinal bleeding benefit from potent acid inhibition. Whereas histamine2‐receptor antagonists have questionable efficacy in preventing ulcer rebleeding in this patient population, PPIs are highly effective. They should be considered first‐line therapy for patients undergoing endoscopic hemostasis and for those with stigmata of upper gastrointestinal bleeding.
- 1 October 2003
- Published by Wiley in Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Vol. 23 (10P2) , 87S-93S
Acid Suppression in Critically Ill Patients: What Does the Evidence Support?
Stress‐related mucosal disease is a frequent complication in critically ill patients. A wealth of evidence suggests that hypoperfusion to the upper gastrointestinal tract can lead to ulceration and is associated with increased morbidity. Management of stress ulcers depends on aggressive therapy that includes acid‐suppressive agents. Proton pump inhibitors (PPIs) have gained recognition as a potentially important therapy for treatment and prevention of upper gastrointestinal bleeding in critically ill patients. Patients who present to the hospital with acute gastrointestinal bleeding benefit from potent acid inhibition. Whereas histamine2‐receptor antagonists have questionable efficacy in preventing ulcer rebleeding in this patient population, PPIs are highly effective. They should be considered first‐line therapy for patients undergoing endoscopic hemostasis and for those with stigmata of upper gastrointestinal bleeding.
- 1 April 2003
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 6 (2) , 135-145
Stress-related mucosal disease
Stress-related mucosal disease (SRMD) includes stress-related injury (superficial mucosal damage) and stress ulcers (focal deep mucosal damage). Both types are caused by mucosal ischemia, and both show a propensity for the acid-producing corpus and fundus. Prophylaxis of stress ulcers may reduce major bleeding but, so far, has not been shown to improve survival. The most widely used drugs for stress-related injury are the intravenous histamine H2-receptor antagonists. Proton pump inhibitors (PPIs) are the most potent acid-suppressive pharmacologic agents. The available PPIs significantly increase gastric pH for up to 24 hours after one dose. Tolerance does not develop, and adverse effects are few. Preliminary studies have demonstrated a significant reduction in SRMD bleeding for patients receiving PPI prophylaxis. PPIs may become an effective tool for reducing the incidence of SRMD in critically ill patients.
- 1 April 2003
- Published by Springer Nature in Current Treatment Options in Gastroenterology
- Vol. 6 (2) , 135-145
Stress-related mucosal disease
Stress-related mucosal disease (SRMD) includes stress-related injury (superficial mucosal damage) and stress ulcers (focal deep mucosal damage). Both types are caused by mucosal ischemia, and both show a propensity for the acid-producing corpus and fundus. Prophylaxis of stress ulcers may reduce major bleeding but, so far, has not been shown to improve survival. The most widely used drugs for stress-related injury are the intravenous histamine H2-receptor antagonists. Proton pump inhibitors (PPIs) are the most potent acid-suppressive pharmacologic agents. The available PPIs significantly increase gastric pH for up to 24 hours after one dose. Tolerance does not develop, and adverse effects are few. Preliminary studies have demonstrated a significant reduction in SRMD bleeding for patients receiving PPI prophylaxis. PPIs may become an effective tool for reducing the incidence of SRMD in critically ill patients.